Expert Review of Anticancer Therapy

Papers
(The TQCC of Expert Review of Anticancer Therapy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence81
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma80
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review44
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence36
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs34
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma31
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?30
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia29
Progress in the development of tissue-based biomarkers for urothelial cancer28
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review28
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects28
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes24
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer24
Current status and novel insights into the role of metastasectomy in the era of immunotherapy24
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma24
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer23
Progress in histology specific treatments in soft tissue sarcoma22
Importance of radiation-related cognitive decline in older adults who receive cranial radiation22
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan21
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis19
Current management of familial adenomatous polyposis18
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma17
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms17
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country15
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population15
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium15
Early detection of hepatocellular carcinoma: roadmap for improvement14
Deciding individual treatment for primary retroperitoneal sarcoma13
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer13
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis13
NRF2/KEAP1 signaling inhibitors in gynecologic cancers13
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image13
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region13
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives12
Management of breast cancer diagnosed during pregnancy: global perspectives12
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis12
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?12
The trend toward more target therapy in pancreatic ductal adenocarcinoma12
Targeting GPRC5D in multiple myeloma12
Current status of robotic surgery for hepato-pancreato-biliary malignancies12
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review11
Novel breakthroughs in advanced prostate cancer management11
PROTACs in action: a novel strategy for pancreatic cancer11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and 11
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy11
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer11
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond11
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?11
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer11
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials10
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)10
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway10
Nivolumab plus ipilimumab in malignant pleural mesothelioma10
Emerging treatment options for prostate cancer10
Genetic investigation in patients with histological variants of bladder cancer: clinical implications10
Anticancer properties of histone deacetylase inhibitors – what is their potential?10
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity10
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?10
Pembrolizumab in the first-line treatment of advanced head and neck cancer10
Interventions to reduce the risk of side-effects of cancer treatments in childhood9
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?9
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies9
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials9
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer9
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol9
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)9
Benign and malignant cardiac masses: long-term outcomes after surgical resection9
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy9
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation9
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers9
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis9
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors9
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials8
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma8
The association between HALP score and survival in patients treated with immune checkpoint inhibitors8
Venetoclax and beyond: New Horizons in CLL and AML therapy8
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy8
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)8
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials8
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?8
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment8
Cemiplimab for locally advanced and metastatic basal cell carcinoma8
Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty8
Oligometastases in head and neck squamous cell carcinoma patients8
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma8
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature8
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review7
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia7
Immune checkpoint inhibition in early-stage triple-negative breast cancer7
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer7
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study7
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations7
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer7
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?7
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer7
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study7
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic7
Medullary thyroid carcinoma: a narrative historical review7
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review7
Circadian rhythm-based cancer therapy in randomised clinical trials7
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review7
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer7
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review6
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma6
Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review6
Addressing the need for more therapeutic options in neuroendocrine prostate cancer6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?6
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis6
Is the ketogenic diet still controversial in cancer treatment?6
The optimal management of brain metastases from gestational trophoblastic neoplasia6
How can we refine the prognostic stratification of triple-negative breast cancer?6
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors6
Primary site and treatment impact in unresectable metastatic colorectal cancer6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis6
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC6
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?6
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies6
Integrating PET/CT into breast cancer care: a review of recent developments6
0.45547819137573